Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Corvus Pharmaceuticals, Inc. (CRVS : NSDQ)

• Company Description    Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California. Number of Employees: 37

• Price / Volume Information    Yesterday's Closing Price: $13.07 Daily Weekly Monthly 20 Day Moving Average: 1,168,549 shares Shares Outstanding: 84.09 (millions) Market Capitalization: $1,099.06 (millions) Beta: 0.82 52 Week High: $26.95 52 Week Low: $3.96 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -3.11% -3.87% 12 Week -15.46% -17.53% Year To Date 69.74% 56.77%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 901 Gateway Boulevard Third Floor - South San Francisco,CA 94080 USA ph: 650-900-4520 fax: - llea@corvuspharma.com http://www.corvuspharma.com

• General Corporate Information    Officers Richard A. Miller - President; Chief Executive Officer and Director Leiv Lea - Chief Financial Officer Ian T. Clark - Director Linda S. Grais - Director Davis Moore - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 221015100 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 84.09 Most Recent Split Date: (:1) Beta: 0.82 Market Capitalization: $1,099.06 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.17 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.70 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.57 Price/Cash Flow: 103.11 Price / Sales: - EPS Growth vs. Year Ago Period: -15.38% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - -38.92 12/31/25 - -23.58 ROA 06/30/26 - - 03/31/26 - -35.75 12/31/25 - -20.60 Current Ratio 06/30/26 - - 03/31/26 - 19.81 12/31/25 - 6.21 Quick Ratio 06/30/26 - - 03/31/26 - 19.81 12/31/25 - 6.21 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - - 03/31/26 - 2.86 12/31/25 - 0.73 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©